Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

Fecha de publicación: 25 de septiembre de 2026, 12:51

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.